GlassScriptPhysician profile
Timothy D Trojan
NPI 1518125053
$12,731.67
in general payments reported to CMS, 2019-2025
32 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $1,130 · 2021: $1,708 · 2022: $3,268 · 2023: $1,598 · 2024: $1,581 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.22 |
| Education | $264.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,767.29 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,702.16 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,273.85 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,111.73 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,006.92 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $786.33 | 2019-2025 | |
| Genzyme Corporation | $746.50 | 2019-2025 | |
| Optinose US, INC. | $590.20 | 2020-2025 | |
| Kaleo, INC. | $551.31 | 2019-2023 | Auvi-Q |
| Amgen INC. | $506.23 | 2019-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $487.47 | 2020-2025 | Cuvitru, Glassia, Eohilia |
| Sanofi-Aventis U.S. LLC | $286.17 | 2021-2025 | |
| Pfizer INC. | $279.75 | 2019-2025 | |
| Alk-Abello, INC | $212.19 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Pharming Healthcare, INC. | $149.69 | 2021-2023 | Ruconest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $140.57 | 2021-2022 | |
| Lilly USA, LLC | $129.86 | 2019-2025 | Ebglyss, Taltz |
| Baxter Healthcare | $117.40 | 2022 | |
| Welch Allyn | $117.40 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $107.90 | 2025 | Neffy |
| Grifols USA, LLC | $107.06 | 2019-2023 | Xembify |
| Blueprint Medicines Corporation | $106.02 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $95.92 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $94.47 | 2020-2022 | |
| Octapharma USA, INC. | $50.67 | 2020-2023 | Panzyga |
| Merck Sharp & Dohme LLC | $44.72 | 2021-2023 | |
| Shire North American Group INC | $43.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2019-2021 | |
| Novo Nordisk INC | $30.09 | 2019 | |
| Greer Laboratories, INC. | $27.12 | 2022 | |
| Uswm, LLC | $16.76 | 2021 | |
| Kedrion Biopharma, INC. | $13.52 | 2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Trojan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.